Drug intelligence / Profile preview

AMG 732

Development stage: Phase 2
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AMG 732 is an investigational monoclonal antibody developed by Amgen for the treatment of thyroid eye disease (Graves ophthalmopathy). Its precise mechanism of action has not been publicly disclosed. The drug is being evaluated in clinical trials to assess its safety, tolerability, pharmacokinetics, and efficacy following subcutaneous administration. As of early 2025, it is in Phase 1/2 clinical development for moderate-to-severe active thyroid eye disease. There are no approved indications or orphan drug designations reported for AMG 732.

Beyond the preview

Go deeper on AMG 732.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 732.

Explore the full profile